Dr. Colm Henry:

We have moved to a lot these recently and we have substituted expensive biolsimilar, expensive medications. We have moved towards a biosimilar use of 80% now, and that is a saving of €80 million. Based on the European Medicines Agency, EMA's, recommendations, we can make that 100%. There are a lot of savings to be made in this area and we are working with clinicians to convert from expensive medications to equally effective and safe biosimilar medications.